Nelistotug

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Lung Cancer, Non-Small CellNeoplasmsNeoplasms, Head and Neck

Phase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Active, not recruitingNCT05277051

GlaxoSmithKlineNeoplasms

Start: 2022-03-22End: 2027-08-31Updated: 2026-03-23

Phase 2

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Active, not recruitingNCT05565378

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2022-10-14End: 2027-02-26Updated: 2026-01-08

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Active, not recruitingNCT06062420

GlaxoSmithKlineNeoplasms, Head and Neck

Start: 2023-11-14End: 2027-07-22Updated: 2026-01-09

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

CompletedNCT06926673

GlaxoSmithKlineNeoplasms

Start: 2021-12-23End: 2024-05-02Updated: 2025-07-03